Publications by authors named "J A Stratmann"
Article Synopsis
- MET amplification in EGFR-mutant non-small cell lung cancer (NSCLC) is a common resistance to EGFR inhibitors, and combining EGFR and MET inhibitors shows promise but has varied definitions of MET amplification.
- In a study of 43 patients with MET copy number gain, those who received the combination of EGFR and MET inhibitors had an 82% clinical benefit rate and longer progression-free survival compared to those receiving MET inhibitors alone or standard of care.
- The findings suggest that true MET amplification drives better outcomes with combination therapy, indicating a need for further research into how different types of MET copy number gain affect treatment response.
Article Synopsis
- In cancer treatment, "lines of therapy" (LOT) is a term that means different things to different doctors, and they don't all agree on its definition.
- A study in Germany found that doctors often have trouble understanding LOT and have had misunderstandings with their colleagues about it.
- Experts discussed various factors that affect LOT, like types of treatments and therapy breaks, but they mostly agreed on what should matter when deciding about LOT.
Lorlatinib is a brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). In clinical trials, lorlatinib has shown durable efficacy and a manageable safety profile in treatment-naive patients and in those who have experienced progression while receiving first- and/or second-generation ALK TKIs. Lorlatinib has a distinct safety profile from other ALK TKIs, including hyperlipidemia and central nervous system effects.
View Article and Find Full Text PDFThe evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown. Here we determined tumour phylogenies at diagnosis and throughout chemotherapy and immunotherapy by multiregion sequencing of 160 tumours from 65 patients. Treatment-naive SCLC exhibited clonal homogeneity at distinct tumour sites, whereas first-line platinum-based chemotherapy led to a burst in genomic intratumour heterogeneity and spatial clonal diversity.
View Article and Find Full Text PDFArticle Synopsis
- - Sotorasib, a KRAS p.G12C-inhibitor, was studied in real-world settings for patients with advanced non-small cell lung cancer (NSCLC) who had received prior treatments, revealing a 38.7% objective response rate and a median overall survival of 9.8 months.
- - Data was collected from 163 patients in a compassionate use program, where a significant portion had poor performance status and existing brain metastases, and some required dose reductions or discontinuation.
- - The study found that factors like PD-L1 expression and KEAP1 mutations influenced efficacy, with KEAP1 mutations associated with worse survival outcomes, while other mutations did not significantly affect response or survival.